Loomis, Sayles & Company
RPRX icon

Loomis, Sayles & Company’s Royalty Pharma RPRX Stock Holding History

Loomis, Sayles & Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
1,971
+420
+27% +$21.9K ﹤0.01% 582
2026
Q1 		$74.4K Buy
+1,551
New +$67.9K ﹤0.01% 606
2024
Q1 		– Sell
-627
Closed -$18K – 919
2023
Q4 		$18K Buy
627
+326
+108% +$8.96K ﹤0.01% 697
2023
Q3 		$8K Hold
301
– – ﹤0.01% 849
2023
Q2 		$9K Sell
301
-34
-10% -$1.15K ﹤0.01% 729
2023
Q1 		$12K Buy
+335
New +$12.4K ﹤0.01% 806
2022
Q4 		– Sell
-38
Closed -$2K – 965
2022
Q3 		$2K Sell
38
-33
-46% -$1.41K ﹤0.01% 841
2022
Q2 		$3K Hold
71
– – ﹤0.01% 783
2022
Q1 		$3K Buy
+71
New +$2.79K ﹤0.01% 896
2021
Q4 		– Sell
-228
Closed -$8K – 881
2021
Q3 		$8K Buy
+228
New +$8.86K ﹤0.01% 870

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's RPRX Position: Q2 2026 in Review

Loomis, Sayles & Company increased its Royalty Pharma (RPRX) stake by 27% in Q2 2026, buying an estimated $21.9K and bringing the position to 1,971 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #582.

Loomis, Sayles & Company first reported a position in RPRX in Q3 2021 and has held it in 10 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Loomis, Sayles & Company held 1,971 shares of Royalty Pharma worth $111K as of Q2 2026.
  • Loomis, Sayles & Company bought 420 Royalty Pharma shares in Q2 2026, an estimated $21.9K.
  • Royalty Pharma made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #582 holding.
  • Loomis, Sayles & Company first reported a position in Royalty Pharma in Q3 2021 and has held it in 10 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.